罗格列酮联合双环醇治疗非酒精性脂肪肝的疗效观察

目的观察罗格列酮联合双环醇治疗非酒精性脂肪肝的临床疗效。方法将65例非酒精性脂肪肝患者随机分为治疗组33例和对照组32例，对照组仅给予常规治疗方法；治疗组在对照组基础上给予罗格列酮和双环醇联合治疗，疗程均为24周。治疗结束后比较两组临床疗效及血清学各指标变化。结果治疗组总有效率84．8％明显优于对照组总有效率71．9％（P〈0．05）；治疗结束后治疗组ALT、AST、TG、TC和LDL-C为（46．46士11．26）U／L，（50．55士14．62）U／L，（1．92士0．32）mmol／L，（4．37±0．38）mmol／L和（2．27±0．41）mmoI／L，较对照组显著降低（P〈0．05），HDL-C为（1．68士0．30）mmol／L，较对照组显著升高（P〈0．05）；治疗期间两组均未见明显不良反应。结论罗格列酮联合双环醇治疗非酒精性脂肪肝疗效显著，可明显改善肝功能和血脂情况，且治疗中无明显副作用，值得在临床推广应用。

Clinical efficacy study of rosiglitazone combined with bicyclol in treatment of non-alcoholic fatty liver

Objective To investigate the clinical efficacy of rosiglitazone combined with bicyclol in treatment of non-alcoholic fatty liver.Methods 65 patients with non-alcoholic fatty liver were randomly divided into treatment group(n=33) and control group(n=32).The control group was only treated with conventional treatment,and the treatment group was treated with rosiglitazone and bicyclol on the basis of control group.The treatment duration lasted 24 weeks for both groups.The clinical efficacy and serological indicators changes of two groups were compared after treatment.Results The total effective rate of treatment group(88.4%) was significantly better than that of control group(74.4%)(P<0.05).The levels of ALT,TC,LDL-C and TG in treatment group after treatment were(47.28±10.41)U/L,(4.28±0.29)mmol/l,(2.25±0.42)mmol/l and(1.96±0.33)mmol/l,which was significantly lower than that of control group,but the levels of HDL-C was(1.69±0.32)mmol/l,which was significantly higher than that of control group(P<0.05);No obvious adverse reactions happened in two groups during treatment.Conclusion The treatment of rosiglitazone combined with bicyclol has a good effect on non-alcoholic fatty liver without adverse reaction.It could significantly improve liver function,blood lipids and imaging.